Update on the treatment of gastrointestinal stromal tumors (GISTs): role of imatinib

References

• JoensuuHFletcherCDimitrijevicSSilbermanSRobertsPDemetriGManagement of malignant gastrointestinal stromal tumorsLancet Oncol200231165566412424067
   PubMed Web of Science ®Google Scholar
• NilssonBBümmingPMeis-KindblomJMGastrointestinal stromal tumors: the incidence, prevalence, clinical course, and prognostication in the preimatinib mesylate era- a population-based study in western SwedenCancer2005103482182915648083
   PubMed Web of Science ®Google Scholar
• JanewayKALieglBHarlowAPediatric KIT wild-type and platelet-derived growth factor receptor alpha-wild-type gastrointestinal stromal tumors share KIT activation but not mechanisms of genetic progression with adult gastrointestinal stromal tumorsCancer Res200767199084908817909012
   PubMed Web of Science ®Google Scholar
• AgaramNPLaquagliaMPUstunBMolecular characterization of pediatric gastrointestinal stromal tumorsClin Cancer Res200814103204321518483389
   PubMed Web of Science ®Google Scholar
• HerreraGACerezoLJonesJEGastrointestinal autonomic nerve tumors. ‘Plexosarcomas’Arch Pathol Lab Med198911388468532757484
   PubMed Web of Science ®Google Scholar
• LauwersGYErlandsonRACasperESBrennanMFWoodruffJMGastrointestinal autonomic nerve tumors. A clinicopathological, immunohistochemical, and ultrastructural study of 12 casesAm J Surg Pathol19931798878978394653
   PubMed Web of Science ®Google Scholar
• HirotaSIsozakiKMoriyamaYGain-of-function mutations of c-kit in human gastrointestinal stromal tumorsScience199827953505775809438854
   PubMed Web of Science ®Google Scholar
• KindblomLGRemottiHEAldenborgFMeis-KindblomJMGastrointestinal pacemaker cell tumor (GIPACT): gastrointestinal stromal tumors show phenotypic characteristics of the interstitial cells of CajalAm J Pathol19981525125912699588894
   PubMed Web of Science ®Google Scholar
• FletcherCDBermanJJCorlessCDiagnosis of gastrointestinal stromal tumors: A consensus approachHum Pathol200233545946512094370
   PubMed Web of Science ®Google Scholar
• MiettinenMLasotaJGastrointestinal stromal tumors: pathology and prognosis at different sitesSemin Diagn Pathol2006232708317193820
   PubMed Web of Science ®Google Scholar
• PengBLloydPSchranHClinical pharmacokinetics of imatinibClin Pharmacokinet200544987989416122278
   PubMed Web of Science ®Google Scholar
• DematteoRPHeinrichMCEl-RifaiWMDemetriGClinical management of gastrointestinal stromal tumors: before and after STI-571Hum Pathol200233546647712094371
   PubMed Web of Science ®Google Scholar
• EisenbergBLHarrisJBlankeCDPhase II trial of neoadjuvant/adjuvant imatinib mesylate (IM) for advanced primary and metastatic/recurrent operable gastrointestinal stromal tumor (GIST): early results of RTOG 0132/ACRIN 6665J Surg Oncol2009991424718942073
   PubMed Web of Science ®Google Scholar
• FioreMPalassiniEFumagalliEPreoperative imatinib mesylate for unresectable or locally advanced primary gastrointestinal stromal tumors (GIST)Eur J Surg Oncol200935773974519110398
   PubMed Web of Science ®Google Scholar
• TherassePArbuckSGEisenhauerEANew guidelines to evaluate the response to treatment in solid tumors. European Organization for Research and Treatment of Cancer, National Cancer Institute of the United States, National Cancer Institute of CanadaJ Natl Cancer Inst200092320521610655437
   PubMed Web of Science ®Google Scholar
• DemetriGDBenjaminRSBlankeCDfor NCCN Task ForceNCCN Task Force report: management of patients with gastrointestinal stromal tumor (GIST)-update of the NCCN clinical practice guidelinesJ Natl Compr Canc Netw20075Suppl 2S12917624289
   PubMedGoogle Scholar
• DemetriGDvon MehrenMBlankeCDEfficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumorsN Engl J Med2002347747248012181401
   PubMed Web of Science ®Google Scholar
• DeMatteoRPLewisJJLeungDMudanSSWoodruffJMBrennanMFTwo hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survivalAnn Surg20002311515810636102
   PubMed Web of Science ®Google Scholar
• DematteoRPBallmanKVAntonescuCRfor American College of Surgeons Oncology Group (ACOSOG) Intergroup Adjuvant GIST Study TeamAdjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trialLancet200937396691097110419303137
   PubMed Web of Science ®Google Scholar
• TuvesonDAWillisNAJacksTSTI571 inactivation of the gastrointestinal stromal tumor c-KIT oncoprotein: biological and clinical implicationsOncogene200120365054505811526490
   PubMed Web of Science ®Google Scholar
• JoensuuHRobertsPJSarlomo-RikalaMEffect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumorN Engl J Med2001344141052105611287975
   PubMed Web of Science ®Google Scholar
• BlankeCDDemetriGDvon MehrenMLong-term results from a randomized phase II trial of standard-versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KITJ Clin Oncol200826462062518235121
   PubMed Web of Science ®Google Scholar
• VerweijJCasaliPGZalcbergJProgression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trialLancet200436494401127113415451219
   PubMed Web of Science ®Google Scholar
• ZalcbergJRVerweijJCasaliPGfor EORTC Soft Tissue and Bone Sarcoma Group, the Italian Sarcoma Group; Australasian Gastrointestinal Trials GroupOutcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mgEur J Cancer200541121751175716098458
   PubMed Web of Science ®Google Scholar
• BlankeCDRankinCDemetriGDPhase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033J Clin Oncol200826462663218235122
   PubMed Web of Science ®Google Scholar
• Van GlabbekeMMOwzarKRankinCSimesJCrowleyJfor GIST Meta-analysis Group (MetaGIST)Comparison of two doses of imatinib for the treatment of unresectable or metastatic gastrointestinal stromal tumors (GIST): A meta-analysis based on 1,640 patients (pts)J Clin Oncol (Meeting Abstracts)20072510004
   Web of Science ®Google Scholar
• ChoiHCharnsangavejCFariaSCCorrelation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteriaJ Clin Oncol200725131753175917470865
   PubMed Web of Science ®Google Scholar
• BenjaminRSChoiHMacapinlacHAWe should desist using RECIST, at least in GISTJ Clin Oncol200725131760176417470866
   PubMed Web of Science ®Google Scholar
• BlayJYLe CesneARay-CoquardIProspective multicentric randomized phase III study of imatinib in patients with advanced gastrointestinal stromal tumors comparing interruption versus continuation of treatment beyond 1 year: the French Sarcoma GroupJ Clin Oncol20072591107111317369574
   PubMed Web of Science ®Google Scholar
• CorlessCLFletcherJAHeinrichMCBiology of gastrointestinal stromal tumorsJ Clin Oncol200422183813382515365079
   PubMed Web of Science ®Google Scholar
• HeinrichMCCorlessCLDemetriGDKinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumorJ Clin Oncol200321234342434914645423
   PubMed Web of Science ®Google Scholar
• HeinrichMCOwzarKCorlessCLCorrelation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology GroupJ Clin Oncol200826335360536718955451
   PubMed Web of Science ®Google Scholar
• Debiec-RychterMSciotRLe CesneAfor EORTC Soft Tissue and Bone Sarcoma Group; Italian Sarcoma Group; Australasian Gastrointestinal Trials GroupKIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumoursEur J Cancer20064281093110316624552
   PubMed Web of Science ®Google Scholar
• PicardSTitierKEtienneGTrough imatinib plasma levels are associated with both cytogenetic and molecular responses to standard-dose imatinib in chronic myeloid leukemiaBlood200710983496349917192396
   PubMed Web of Science ®Google Scholar
• LarsonRADrukerBJGuilhotFfor IRIS (International Randomized Interferon vs STI571) Study GroupImatinib pharmaco-kinetics and its correlation with response and safety in chronic-phase chronic myeloid leukemia: a subanalysis of the IRIS studyBlood200811184022402818256322
   PubMed Web of Science ®Google Scholar
• DemetriGDWangYWehrleEImatinib plasma levels are correlated with clinical benefit in patients with unresectable/metastatic gastrointestinal stromal tumorsJ Clin Oncol200927193141314719451435
   PubMed Web of Science ®Google Scholar
• HeinrichMCCorlessCLBlankeCDMolecular correlates of imatinib resistance in gastrointestinal stromal tumorsJ Clin Oncol200624294764477416954519
   PubMed Web of Science ®Google Scholar
• LieglBKeptenILeCHeterogeneity of kinase inhibitor resistance mechanisms in GISTJ Pathol20082161647418623623
   PubMed Web of Science ®Google Scholar
• AntonescuCRBesmerPGuoTAcquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutationClin Cancer Res200511114182419015930355
   PubMed Web of Science ®Google Scholar
• DesaiJShankarSHeinrichMCClonal evolution of resistance to imatinib in patients with metastatic gastrointestinal stromal tumorsClin Cancer Res200713185398540517875769
   PubMed Web of Science ®Google Scholar
• RautCPPosnerMDesaiJSurgical management of advanced gastrointestinal stromal tumors after treatment with targeted systemic therapy using kinase inhibitorsJ Clin Oncol2006241523252323116710031
   PubMed Web of Science ®Google Scholar
• DemetriGDvan OosteromATGarrettCREfficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trialLancet200636895441329133817046465
   PubMed Web of Science ®Google Scholar
• DemetriGDHeinrichMCFletcherJAMolecular target modulation, imaging, and clinical evaluation of gastrointestinal stromal tumor patients treated with sunitinib malate after imatinib failureClin Cancer Res200915185902590919737946
   PubMed Web of Science ®Google Scholar
• GeorgeSBlayJYCasaliPGClinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failureEur J Cancer200945111959196819282169
   PubMed Web of Science ®Google Scholar
• HeinrichMCMakiRGCorlessCLPrimary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumorJ Clin Oncol200826335352535918955458
   PubMed Web of Science ®Google Scholar
• GajiwalaKSWuJCChristensenJKIT kinase mutants show unique mechanisms of drug resistance to imatinib and sunitinib in gastrointestinal stromal tumor patientsProc Natl Acad Sci U S A200910651542154719164557
   PubMed Web of Science ®Google Scholar
• MiettinenMLasotaJSobinLHGastrointestinal stromal tumors of the stomach in children and young adults: a clinicopathologic, immunohistochemical, and molecular genetic study of 44 cases with long-term follow-up and review of the literatureAm J Surg Pathol200529101373138116160481
   PubMed Web of Science ®Google Scholar
• JanewayKAAlbrittonKHVan Den AbbeeleADSunitinib treatment in pediatric patients with advanced GIST following failure of imatinibPediatr Blood Cancer200952776777119326424
   PubMed Web of Science ®Google Scholar
• TarnCRinkLMerkelEInsulin-like growth factor 1 receptor is a potential therapeutic target for gastrointestinal stromal tumorsProc Natl Acad Sci U S A2008105248387839218550829
   PubMed Web of Science ®Google Scholar
• CorlessCLBeadlingCJustussonEHeinrichMCEvaluation of the presence of IGF1R overexpression in wild-type and kinase mutant GI stromal tumorsJ Clin Oncol (Meeting Abstracts)20092710506
   Web of Science ®Google Scholar
• AgaramNPWongGCGuoTNovel V600E BRAF mutations in imatinib-naive and imatinib-resistant gastrointestinal stromal tumorsGenes Chromosomes Cancer2008471085385918615679
   PubMed Web of Science ®Google Scholar
• KleinbaumEPLazarAJTamboriniEClinical, histopathologic, molecular and therapeutic findings in a large kindred with gastrointestinal stromal tumorInt J Cancer2008122371171817943734
   PubMed Web of Science ®Google Scholar
• LiFPFletcherJAHeinrichMCFamilial gastrointestinal stromal tumor syndrome: phenotypic and molecular features in a kindredJ Clin Oncol200523122735274315837988
   PubMed Web of Science ®Google Scholar
• ChompretAKannengiesserCBarroisMPDGFRA germline mutation in a family with multiple cases of gastrointestinal stromal tumorGastroenterology2004126131832114699510
   PubMed Web of Science ®Google Scholar
• CarneyJAGastric stromal sarcoma, pulmonary chondroma, and extra-adrenal paraganglioma (Carney Triad): natural history, adrenocortical component, and possible familial occurrenceMayo Clin Proc199974654355210377927
   PubMed Web of Science ®Google Scholar
• ZöllerMERembeckBOdénAMalignant and benign tumors in patients with neurofibromatosis type 1 in a defined Swedish populationCancer19977911212521319179058
   PubMed Web of Science ®Google Scholar
• MiettinenMFetschJFSobinLHGastrointestinal stromal tumors in patients with neurofibromatosis 1: a clinicopathologic and molecular genetic study of 45 casesAm J Surg Pathol2006301909616330947
   PubMed Web of Science ®Google Scholar
• WiebeLKaszaKEMakiRGActivity of sorafenib (SOR) in patients (pts) with imatinib (IM) and sunitinib (SU)-resistant (RES) gastrointestinal stromal tumors (GIST): A phase II trial of the University of Chicago Phase II ConsortiumJ Clin Oncol (Meeting Abstracts)20082610502
   Web of Science ®Google Scholar
• ReichardtPMontemurroMGelderblomHSorafenib fourth-line treatment in imatinib-, sunitinib-, and nilotinib-resistant metastatic GIST: A retrospective analysisJ Clin Oncol (Meeting Abstracts)20092710564
   Google Scholar
• HeinrichMCCardenRGriffithDIn vitro activity of sorafenib against imatinib- and sunitinib-resistant kinase mutations associated with drug-resistant GI stromal tumorsJ Clin Oncol (Meeting Abstracts)20092710500
   Web of Science ®Google Scholar
• BlayJYCasaliPGReichardtPA phase I study of nilotinib alone and in combination with imatinib in patients with imatinib-resistant gastrointestinal stromal tumors (GIST): Study updateJ Clin Oncol (Meeting Abstracts)20082610553
   Web of Science ®Google Scholar
• SoriaJCMassardCMagnéNPhase 1 dose-escalation study of oral tyrosine kinase inhibitor masitinib in advanced and/or metastatic solid cancersEur J Cancer200945132333234119541476
   PubMed Web of Science ®Google Scholar
• Le CesneABlayJBuiNBMasatinib mesylate in imatinib-naive locally advanced or metastatic gastrointestinal stromal tumor (GIST): Results of the French Sarcoma Group phase II trialJ Clin Oncol (Meeting Abstracts)20092710507
   Web of Science ®Google Scholar
• WhitesellLLindquistSLHSP90 and the chaperoning of cancerNat Rev Cancer200551076177216175177
   PubMed Web of Science ®Google Scholar
• BauerSYuLKDemetriGDFletcherJAHeat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumorCancer Res200666189153916116982758
   PubMed Web of Science ®Google Scholar
• WagnerAJMorganJAChughRInhibition of heat shock protein 90 (Hsp90) with the novel agent IPI-504 in metastatic GIST following failure of tyrosine kinase inhibitors (TKIs) or other sarcomas: Clinical results from phase I trialJ Clin Oncol (Meeting Abstracts)20082610503
   Web of Science ®Google Scholar
• YoungHBaumRCremeriusUMeasurement of clinical and subclinical tumour response using [18F]-fluorodeoxyglucose and positron emission tomography: review and 1999 EORTC recommendations. European Organization for Research and Treatment of Cancer (EORTC) PET Study GroupEur J Cancer199935131773178210673991
   PubMed Web of Science ®Google Scholar
• BauerSDuensingADemetriGDFletcherJAKIT oncogenic signaling mechanisms in imatinib-resistant gastrointestinal stromal tumor: PI3-kinase/AKT is a crucial survival pathwayOncogene200726547560756817546049
   PubMed Web of Science ®Google Scholar
• DumezHReichardPBlayJYfor CRAD001C2206 Study GroupA phase I-II study of everolimus (RAD001) in combination with imatinib in patients (pts) with imatinib-resistant gastrointestinal stromal tumors (GIST)J Clin Oncol (Meeting Abstracts)20082610519
   Web of Science ®Google Scholar
• RubinBPHeinrichMCCorlessCLGastrointestinal stromal tumourLancet200736995741731174117512858
   PubMed Web of Science ®Google Scholar